![Ann Hanham](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ann Hanham
Direktor/Vorstandsmitglied bei
SCYNEXIS, INC.
Vermögen: 56 033 $ am 31.07.2026
Profil
Ann F.
Hanham was the founder of InterMune, Inc., founded in 1998, serving as Vice President-Clinical & Regulatory Affairs from 1998 to 2000.
Current job includes Independent Director at SCYNEXIS, Inc. since 2008.
Former jobs include Chairman at Adlyfe, Inc.; Medical Director at Celtrix Pharmaceuticals, Inc. from 1991 to 1995; Director roles at Acusphere, Inc., Immunicon Corp., Sention, Inc., Aerovance, Inc., Waterstone Pharmaceuticals, Inc., Veritas Medicine, Inc., Logical Therapeutics, Inc., NewBridge Pharmaceuticals FZ LLC, Taiwan Liposome Co., Ltd.; Director at BioMimetic Therapeutics, Inc. in 2006; Managing Director & General Partner at Burrill LLC from 2000 to 2013; Director at Biotie Therapies Oy in 2010; Director at Targacept, Inc. in 2006; Independent Director at Endocyte, Inc. from 2011 to 2018; Senior Director-Oncology Product Development at Otsuka America Pharmaceutical, Inc. from 1995 to 1998; Managing Director & Founding Partner at BAR Capital Management LLC from 2013 to 2016; Lead Independent Director at HTG Molecular Diagnostics, Inc. from 2019 to 2021; Senior Manager-Medical Affairs at Becton, Dickinson & Co. from 1984 to 1991; Managing Partner at Bar Capital LLC from 2013 to 2017.
Education includes a doctorate from the University of British Columbia, graduate studies at Simon Fraser University, and undergraduate studies at the University of Toronto.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
SCYNEXIS, INC. 0.12% | 26.06.2026 | 11’577 ( 0.12% ) | 56 033 $ | 31.07.2026 |
Aktive Positionen von Ann Hanham
| Unternehmen | Position | Beginn |
|---|---|---|
| SCYNEXIS, INC. | Direktor/Vorstandsmitglied | 01.12.2008 |
Ehemalige bekannte Positionen von Ann Hanham
| Unternehmen | Position | Ende |
|---|---|---|
| ENDOCYTE, INC. | Direktor/Vorstandsmitglied | 01.01.2018 |
Bar Capital LLC | Corporate Officer/Principal | 01.03.2017 |
BAR Capital Management LLC
 BAR Capital Management LLC Investment ManagersFinance BAR Capital Management LLC invests in companies located globally. The firm focuses on companies operating in the fields of biotechnology, pharmaceuticals, diagnostics, medical devices, human healthcare & related medical technologies, wellness & nutraceuticals, agbio and industrial biotechnology (biomaterials/bioprocess). It provides financing for seed, early stage and mezzanine capital requirements with an investment size ranging between $1 and $20 million per company. | Corporate Officer/Principal | 31.12.2016 |
Burrill LLC
 Burrill LLC Investment ManagersFinance Burrill invests in companies located in the United States. The firm focuses on a broad range of sectors. It participates in buyout and early-stage transactions. | Vorstandsvorsitzender | 01.11.2013 |
Veritas Medicine, Inc.
 Veritas Medicine, Inc. Internet Software/ServicesTechnology Services Operates an online database of clinical trials | Direktor/Vorstandsmitglied | 16.05.2011 |
Ausbildung von Ann Hanham
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
74
Beziehungen ersten Grades
26
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 26 |
|---|---|
Becton, Dickinson & Co.
 Becton, Dickinson & Co. Medical SpecialtiesHealth Technology Manufactures and sells medical supplies, devices, laboratory equipment & diagnostic products | Health Technology |
Celtrix Pharmaceuticals, Inc.
 Celtrix Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Researches and develops potential therapeutic products | Health Technology |
InterMune, Inc.
 InterMune, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that researches and develops therapies in pulmonology & orphan fibrotic diseases | Health Technology |
Acusphere, Inc.
 Acusphere, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes drugs | Health Technology |
Immunicon Corp.
 Immunicon Corp. Medical SpecialtiesHealth Technology Develops cell-based research and diagnostic products | Health Technology |
Sention, Inc.
 Sention, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals products | Health Technology |
Aerovance, Inc.
 Aerovance, Inc. Medical DistributorsDistribution Services Develops drugs for respiratory and inflammatory diseases | Distribution Services |
HTG Molecular Diagnostics, Inc.
 HTG Molecular Diagnostics, Inc. Miscellaneous Commercial ServicesCommercial Services Provides molecular technology solutions | Commercial Services |
BioMimetic Therapeutics, Inc.
 BioMimetic Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and sells protein therapeutics for tissue and organ regeneration | Health Technology |
Adlyfe, Inc.
 Adlyfe, Inc. Medical DistributorsDistribution Services Develops diagnostic products | Distribution Services |
Waterstone Pharmaceuticals, Inc.
 Waterstone Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in activities ranging from drug discovery of proprietary new chemical entities, custom development and manufacturing services, and generic drug development and manufacturing | Health Technology |
Burrill LLC
Burrill LLC Investment ManagersFinance Burrill invests in companies located in the United States. The firm focuses on a broad range of sectors. It participates in buyout and early-stage transactions. | Finance |
Biotie Therapies Oy
 Biotie Therapies Oy Pharmaceuticals: MajorHealth Technology Engages in research, development and commercialization of pharmaceutical products | Health Technology |
SCYNEXIS, Inc.
 SCYNEXIS, Inc. Pharmaceuticals: MajorHealth Technology Develops novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections | Health Technology |
Targacept, Inc.
 Targacept, Inc. Pharmaceuticals: OtherHealth Technology Discovers and develops nicotinic acetylcholine receptor based therapies | Health Technology |
University of British Columbia
 University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Simon Fraser University
 Simon Fraser University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Toronto
 University of Toronto Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Veritas Medicine, Inc.
Veritas Medicine, Inc. Internet Software/ServicesTechnology Services Operates an online database of clinical trials | Technology Services |
Endocyte, Inc.
 Endocyte, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for cancer and inflammatory diseases | Health Technology |
Otsuka America Pharmaceutical, Inc.
 Otsuka America Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and supplies pharmaceutical products | Health Technology |
Logical Therapeutics, Inc.
 Logical Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops products that treat diseases associated with inflammation | Health Technology |
NewBridge Pharmaceuticals FZ LLC
 NewBridge Pharmaceuticals FZ LLC Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceuticals, therapeutics, and medical devices | Health Technology |
Taiwan Liposome Co., Ltd.
 Taiwan Liposome Co., Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company | Health Technology |
BAR Capital Management LLC
BAR Capital Management LLC Investment ManagersFinance BAR Capital Management LLC invests in companies located globally. The firm focuses on companies operating in the fields of biotechnology, pharmaceuticals, diagnostics, medical devices, human healthcare & related medical technologies, wellness & nutraceuticals, agbio and industrial biotechnology (biomaterials/bioprocess). It provides financing for seed, early stage and mezzanine capital requirements with an investment size ranging between $1 and $20 million per company. | Finance |
Bar Capital LLC |
